LLY

986.21

-0.95%↓

JNJ

240.82

-0.44%↓

ABBV

225.01

-0.25%↓

NVS

154.16

-0.71%↓

AZN

191.85

-0.27%↓

LLY

986.21

-0.95%↓

JNJ

240.82

-0.44%↓

ABBV

225.01

-0.25%↓

NVS

154.16

-0.71%↓

AZN

191.85

-0.27%↓

LLY

986.21

-0.95%↓

JNJ

240.82

-0.44%↓

ABBV

225.01

-0.25%↓

NVS

154.16

-0.71%↓

AZN

191.85

-0.27%↓

LLY

986.21

-0.95%↓

JNJ

240.82

-0.44%↓

ABBV

225.01

-0.25%↓

NVS

154.16

-0.71%↓

AZN

191.85

-0.27%↓

LLY

986.21

-0.95%↓

JNJ

240.82

-0.44%↓

ABBV

225.01

-0.25%↓

NVS

154.16

-0.71%↓

AZN

191.85

-0.27%↓

Search

Sana Biotechnology Inc

Avatud

SektorTervishoid

3.09 -4.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.07

Max

3.25

Põhinäitajad

By Trading Economics

Sissetulek

-17M

-59M

Töötajad

142

EBITDA

-11M

-50M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+188.75% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. märts 2026

Turustatistika

By TradingEconomics

Turukapital

-217M

889M

Eelmine avamishind

7.13

Eelmine sulgemishind

3.09

Uudiste sentiment

By Acuity

50%

50%

147 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. märts 2026, 19:18 UTC

Suurimad hinnamuutused turgudel

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11. märts 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

11. märts 2026, 23:54 UTC

Market Talk

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11. märts 2026, 23:51 UTC

Market Talk

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11. märts 2026, 23:41 UTC

Market Talk

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11. märts 2026, 23:37 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11. märts 2026, 23:17 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11. märts 2026, 22:29 UTC

Market Talk

Australia Shares Set to Fall in Early Trade -- Market Talk

11. märts 2026, 21:47 UTC

Tulu

Liontown Resources: Market Tailwinds Strengthening Outlook

11. märts 2026, 21:46 UTC

Tulu

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources Says FY26 Guidance Unchanged

11. märts 2026, 21:45 UTC

Tulu

Liontown Resources 1H Unit Operating Costs A$985/Ton

11. märts 2026, 21:44 UTC

Tulu

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Revenue A$207.5 Million

11. märts 2026, 21:43 UTC

Tulu

Liontown Resources 1H Net Loss A$184 Million

11. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss $7.5M >VGZ

11. märts 2026, 21:10 UTC

Tulu

Vista Gold FY25 Loss/Shr 6c >VGZ

11. märts 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

11. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

11. märts 2026, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11. märts 2026, 20:26 UTC

Tulu

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11. märts 2026, 20:19 UTC

Uudisväärsed sündmused

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11. märts 2026, 20:15 UTC

Tulu

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11. märts 2026, 20:12 UTC

Uudisväärsed sündmused

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11. märts 2026, 19:31 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11. märts 2026, 19:01 UTC

Market Talk
Uudisväärsed sündmused

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11. märts 2026, 18:59 UTC

Omandamised, ülevõtmised, äriostud

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

188.75% tõus

12 kuu keskmine prognoos

Keskmine 9.5 USD  188.75%

Kõrge 12 USD

Madal 7 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.68 / 1.87Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

147 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat